摘要
目的:观察血必净注射液对晚期实体瘤相关类白血病反应的临床疗效。方法:将符合纳入标准的晚期实体瘤相关类白血病反应患者60例随机分为治疗组32例和对照组28例,在常规抗感染、对症支持治疗的基础上,治疗组加用血必净注射液50m L静脉滴注,每天2次,连续治疗14天。2组患者治疗前、治疗7天后、治疗14天后分别采血检测白细胞计数(WBC)、C-反应蛋白(CRP)、降钙素原(PCT)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、血浆凝血酶原时间(PT)和活化部分凝血酶原时间(APTT),并记录观察期间的死亡率。结果:与治疗前比较,治疗14天后治疗组WBC、CRP、PCT、TNF-α、IL-6、PT和APTT均下降,差异均有统计学意义(P<0.05);治疗14天后,治疗组WBC、CRP、PCT、TNF-α、IL-6及APTT与对照组比较,差异均有统计学意义(P<0.05)。观察期内治疗组死亡率低于对照组,差异有统计学意义(P<0.05)。结论:血必净注射液可有效降低晚期实体瘤相关类白血病反应患者外周血中相关炎性介质的表达,减轻全身炎症反应,降低出血风险,改善预后。
Objective： To observe the clinical effect of Xuebijing injection on advanced solid tumor related leukemoid reaction.Methods：Divided 60 cases of patients with advanced solid tumor related leukemoid reaction according with standard into the treatment group of 32 cases and the control group of 28 cases randomly. The treatment group additionally received Xuebijing injection 50 ml intravenous drip on the basis of the treatment of anti-infection and palliatively supporting twice a day for consecutive 14 days. While before treatment,7 days after treatment and 14 days after treatment,determined white blood cell（WBC） count, C-reactive protein（CRP）,procalcitonin（PCT）,tumor necrosis factor-α（TNF-α）,prothrombin time（PT） and activated partial thromboplastin time（APTT）in both groups,and recorded the death rate during the observation period. Results：Comparing with those before treatment,WBC,CRP, PCT, TNF-α, IL-6, PT and APTT were all decreased 14 days after treatment, differences being significant（P 〈0.05）.Compared WBC、CRP、PCT、TNF-α,IL-6 and APTT of the treatment group with those of the control group 14 days after treatment,the differences being significant（P〈0.05）. The death rate during the observation period of the treatment group was lower than that of the control group,the difference being significant（P〈0.05）. Conclusion：Xuebijing injection can effectively reduce the expression of related inflammatory mediators in peripheral blood in patients with advanced solid tumor related leukemoid reaction, relieve systemic inflammatory reaction,bring down the risk of hemorrhage and improve prognosis.
出处
《新中医》
CAS
2017年第2期118-121,共4页
New Chinese Medicine
